Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-10T14:05:39.550Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients with Schizophrenia or Schizoaffective Disorder: Results of a Double-Blind, Six-WeekStudy, with a Six-Month, Double-Blind Continuation Phase

Published online by Cambridge University Press:  02 March 2006

George M. Simpson ,
Antony Loebel ,
Lewis Warrington  and
Ruoyong Yang
George M. Simpson
Affiliation:
Department of Psychiatry and the Behavioral Sciences, LAC + USC Medical Center, Psychiatric Outpatient Clinic, Los Angeles, CA, USA; Email: gsimpson@hsc.usc.edu
Antony Loebel
Affiliation:
Pfizer Inc, NY, USA
Lewis Warrington
Affiliation:
Pfizer Inc, NY, USA
Ruoyong Yang
Affiliation:
Pfizer Inc, NY, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Olanzapinezisprasidoneschizophreniaschizoaffective disordersclinical trialneurotherapeutics
Type
Review Article
Information
Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 1 , Issue 1 , January 2006 , pp. 149 - 163
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Studyof Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.Google Scholar
Casey, D.E., Haupt, D.W., Newcomer, J.W., Henderson, D.C., Sernyak, M.J., Davidson, M., Lindenmayer, J.P., Manoukian, S.V., Banerji, M.A., Lebovitz, H.E., & Hennekens, C.H. (2004). Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. Journal of Clinical Psychiatry, 65 (Suppl. 7), 4–18.Google Scholar
Cochrane Group. (2005). Risperidone versus olanzapine for schizophrenia. Cochrane Database System Review, April 18; (2): CD005237.Google Scholar
Davidson, S., Judd, F., Jolley, D., Hocking, B., Thompson, S., & Hyland, B. (2001). Cardiovascular risk factors for people with mental illness. Australian and New Zealand Journal of Psychiatry, 35, 196–202.Google Scholar
Harris, E.C., & Barraclough, B. (1998). Excess mortality of mental disorder. British Journal of Psychiatry, 173, 11–53.Google Scholar
Harrison, D.J., Leaderer, M.C., Loebel, A., & Murray, S. (2004). Ziprasidone vs. olanzapine: change in CHD risk during a 6-week trial. Poster presentation, 157th Annual Meeting of the American Psychiatric Association, New York, May.
Harrison, D.J., Joyce, A.T., & Ollendorf, D.A. (2005). Impact of Atypical Agents on Outcomes of Care in Schizophrenia. Poster presentation, 158th Annual Meeting of the American Psychiatric Association, Atlanta, May.
Harvey, P.D., Bowie, C.R., & Loebel, A. (in press). Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a 6-month, randomized, double-blind comparison of ziprasidone vs. Olanzapine.
Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2001). Mental disorders and cause-specific mortality. British Journal of Psychiatry, 179, 498–502.Google Scholar
Joyce, A.T., Harrison, D.J., & Ollendorf, D.A. (2004). Effect of ziprasidone initial dosing on discontinuation. Poster presentation, 157th Annual Meeting of the American Psychiatric Association, New York, May.
Marder, S.R., McQuade, R.D., Stock, E., Kaplita, S., Marcus, R., Safferman, A.Z., Saha, A., Ali, M., & Iwamoto, T. (2003). Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Research, 61, 123–136.Google Scholar
Marder, S.R., Essock, S.M., Miller, A.L., Buchanan, R.W., Casey, D.E., Davis, J.M., Kane, J.M., Lieberman, J.A., Schooler, N.R., Covell, N., Stroup, S., Weissman, E.M., Wirshing, D.A., Hall, C.S., Pogach, L., Pi-Sunyer, X., Bigger, J.T. Jr., Friedman, A., Kleinberg, D., Yevich, S.J., Davis, B., & Shon, S. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161, 1334–1349.Google Scholar
Newcomer, J.W. (2005). Atypical antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19 (suppl 1): 1–93.Google Scholar
Ryan, M.C., Collins, P., & Thakore, J.H. (2003). Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry, 160, 284–289.Google Scholar
Simpson, G.M., Glick, I.D., Weiden, P.J., Romano, S.J., & Siu, C.O. (2004). Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 161, 1837–1847.Google Scholar
Simpson, G.M., Weiden, P., Pigott, T., Murray, S., Siu, C.O., & Romano, S.J. (2005). Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. American Journal of Psychiatry, 162, 1535–1538.Google Scholar
Sorensen, S.V., Leaderer, M.C., Harrison, D.J., Prasad, M., Hollenbeak, C., Dugar, A., & Remak, E. (2004). Psychiatric and metabolic outcomes of antipsychotics in schizophrenia. Poster presentation, 157th Annual Meeting of the American Psychiatric Association, New York, May.
Tuunainen, A., Wahlbeck, K., & Gilbody, S. (2002). Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophrenia Research, 56, 1–10.Google Scholar
Weiden, P.J., Iqbal, N., Mendelowitz, A.J., Tandon, R., Zimbroff, D.L., & Ross, R. (2002). Best clinical practice with ziprasidone: update after one year of experience. Journal of Psychiatric Practice, 8, 81–97.Google Scholar
Wilson, P.W., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., & Kannel, W.B. (1998). Prediction of coronary heart disease using risk factor categories. Circulation, 97, 1837–1847.Google Scholar
Wolf, P.A., Abbott, R.D., & Kannel, W.B. (1991). Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 22, 983–988.Google Scholar